Resistance to Immunotherapeutic Antibodies in Cancer / Resistance to Targeted Anti-Cancer Therapeutics Bd.2 (PDF)

Name: Resistance to Immunotherapeutic Antibodies in Cancer / Resistance to Targeted Anti-Cancer Therapeutics Bd.2
Brand: Springer-Verlag GmbH
SKU: 52018892
Price: 153.99 EUR
Availability: OnlineOnly

Strategies to Overcome Resistance (Sprache: Englisch)

Schreiben Sie einen Kommentar zu "Resistance to Immunotherapeutic Antibodies in Cancer / Resistance to Targeted Anti-Cancer Therapeutics Bd.2".

Merken

Mehr zum Inhalt Autorenporträt Video

eBook (pdf) 153.99 €

Buch (Gebunden) 164.99 €

sofort als Download lieferbar

Bestellnummer: 52018892

Printausgabe 164.99 €

eBook (pdf) -7% 153.99 €

Download bestellen

Verschenken

Lastschrift, Kreditkarte, Paypal, Rechnung
Kostenloser tolino webreader

Produktdetails

Produktbeschreibung
Autorenporträt
eBook Hilfe
Biblio. Angaben / Produktdetails

Produktinformationen zu „Resistance to Immunotherapeutic Antibodies in Cancer / Resistance to Targeted Anti-Cancer Therapeutics Bd.2 (PDF)“

The current application of antibody-meditated targeted therapy against cancer has resulted in significant objective clinical responses, prolongation of survival and even cures. More than 20 mAbs have been approved for human use targeting a range of different cancers. However, a major drawback of mAb therapeutics is that a subset of patients does not initially respond and another initially responding subset develops resistance to further treatments. At the present time, there are no effective therapies for these subsets of cancer patients. The analyses of underlying mechanisms responsible for resistance are necessary to develop and generate new targeted therapies that overcome the resistance.

Resistance to Immunotherapeutic Antibodies in Cancer: Strategies to Overcome Resistance is a timely volume that deals with various mechanisms of resistance to anti-cancer mAbs therapeutics as well as it deals with novel approaches to overcome resistance. The reviews in this volume are written by highly qualified, established and experienced leaders in the field of resistance to anti-cancer mAbs.

Autoren-Porträt

Dr. Benjamin Bonavida is a professor at UCLA's David Geffen School of Medicine for the Department of Microbiology, Immunology, & Molecular Genetics. His other appointments include being a member of the Department of Defense Congressionally Directed Medical Research Program, Member of the National Cancer Institute's SPORE Program, member of the International Scientific Advisory Board of the Israel Cancer Research Foundation, to name a few. He's currently a scientific reviewer for several journals and a member of editorial boards including Journal of Clinical Immunology, International Journal of Oncology, and Cancer Biotherapy & Radiopharmaceuticals. In his career, he's published over 450 papers and reviews, and he's also edited two books with Springer in the past. For more information, please see the CV attached herewith.